NASDAQ:FIXX Homology Medicines (FIXX) Stock Forecast, Price & News $0.98 -0.01 (-1.01%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$0.98▼$1.0350-Day Range$0.92▼$1.0852-Week Range$0.86▼$3.30Volume55,704 shsAverage Volume128,635 shsMarket Capitalization$56.92 millionP/E RatioN/ADividend YieldN/APrice Target$6.85 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Homology Medicines MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside786.1% Upside$8.73 Price TargetShort InterestHealthy0.64% of Float Sold ShortDividend StrengthN/ASustainability-0.33Upright™ Environmental ScoreNews Sentiment0.00Based on 2 Articles This WeekInsider TradingSelling Shares$15,899 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.82) to ($1.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.57 out of 5 starsMedical Sector109th out of 983 stocksPharmaceutical Preparations Industry41st out of 486 stocks 3.3 Analyst's Opinion Consensus RatingHomology Medicines has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.73, Homology Medicines has a forecasted upside of 786.1% from its current price of $0.99.Amount of Analyst CoverageHomology Medicines has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.64% of the float of Homology Medicines has been sold short.Short Interest Ratio / Days to CoverHomology Medicines has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Homology Medicines has recently decreased by 23.42%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldHomology Medicines does not currently pay a dividend.Dividend GrowthHomology Medicines does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHomology Medicines has received a 78.74% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Homology Medicines is -0.33. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Homology Medicines this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for FIXX on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Homology Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,899.00 in company stock.Percentage Held by Insiders22.50% of the stock of Homology Medicines is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions40.73% of the stock of Homology Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Homology Medicines are expected to grow in the coming year, from ($1.82) to ($1.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Homology Medicines is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Homology Medicines is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHomology Medicines has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Homology Medicines (NASDAQ:FIXX) StockHomology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the translation of proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. The company was founded in March 2015 and is headquartered in Bedford, MA.Read More Receive FIXX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Homology Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address FIXX Stock News HeadlinesMay 30, 2023 | americanbankingnews.comHomology Medicines, Inc. (NASDAQ:FIXX) Receives $8.73 Average Target Price from AnalystsMay 27, 2023 | americanbankingnews.comReviewing Homology Medicines (NASDAQ:FIXX) & Ayala Pharmaceuticals (OTCMKTS:ADXS)June 2, 2023 | Stocks To Trade (Ad)Free SMS Trade Alerts. Up to 15 opportunities a day.Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 19, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Homology Medicines, Inc. (NASDAQ:FIXX) Raised by AnalystMay 16, 2023 | finance.yahoo.comHomology Medicines Announces First Data from IND-Enabling Studies with GTx-mAb Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, at the ASGCT Annual MeetingMay 16, 2023 | americanbankingnews.comHomology Medicines, Inc. (NASDAQ:FIXX) Forecasted to Post FY2027 Earnings of $1.06 Per ShareMay 15, 2023 | markets.businessinsider.comHomology Medicines (FIXX) Gets a Hold from RBC CapitalMay 15, 2023 | msn.comHC Wainwright & Co. Reiterates Homology Medicines (FIXX) Buy RecommendationJune 2, 2023 | Stocks To Trade (Ad)Free SMS Trade Alerts. Up to 15 opportunities a day.Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 15, 2023 | markets.businessinsider.comRobert W. Baird Sticks to Their Buy Rating for Homology Medicines (FIXX)May 12, 2023 | msn.comChardan Capital Maintains Homology Medicines (FIXX) Buy RecommendationMay 12, 2023 | msn.comCredit Suisse Reiterates Homology Medicines (FIXX) Neutral RecommendationMay 12, 2023 | markets.businessinsider.comCredit Suisse Keeps Their Hold Rating on Homology Medicines (FIXX)May 12, 2023 | finanznachrichten.deHomology Medicines, Inc.: Homology Medicines Reports First Quarter 2023 Financial Results and Recent HighlightsMay 11, 2023 | technews.tmcnet.comHomology Medicines Reports First Quarter 2023 Financial Results and Recent HighlightsMay 11, 2023 | seekingalpha.comHomology Medicines GAAP EPS of -$0.50 beats by $0.04, revenue of $0.8M misses by $0.21MMay 8, 2023 | americanbankingnews.comBrokerages Set Homology Medicines, Inc. (NASDAQ:FIXX) Price Target at $8.73May 3, 2023 | tmcnet.comHomology Medicines Announces Upcoming Presentations Highlighting its GeneticMay 3, 2023 | finance.yahoo.comHomology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual MeetingApril 15, 2023 | americanbankingnews.comHomology Medicines, Inc. (NASDAQ:FIXX) Receives Average Rating of "Moderate Buy" from AnalystsApril 7, 2023 | americanbankingnews.comHomology Medicines (NASDAQ:FIXX) Price Target Lowered to $7.00 at FIXApril 3, 2023 | markets.businessinsider.comBTIG Sticks to Its Buy Rating for Homology Medicines (FIXX)March 27, 2023 | finance.yahoo.comBridgeBio Pharma (BBIO) Moves 9.7% Higher: Will This Strength Last?March 21, 2023 | americanbankingnews.comHomology Medicines, Inc. (NASDAQ:FIXX) Receives $8.51 Consensus Price Target from AnalystsMarch 21, 2023 | americanbankingnews.comQ1 2023 EPS Estimates for Homology Medicines, Inc. Decreased by HC Wainwright (NASDAQ:FIXX)March 15, 2023 | tmcnet.comHomology Medicines Announces Presentations on Design of OngoingMarch 15, 2023 | finance.yahoo.comHomology Medicines Announces Presentations on Design of Ongoing Gene Editing and Gene Therapy Trials for PKU and Hunter Syndrome at ACMG Annual Clinical Genetics MeetingSee More Headlines FIXX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FIXX Company Calendar Last Earnings3/09/2023Today6/02/2023Next Earnings (Estimated)8/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FIXX CUSIPN/A CIK1661998 Webwww.homologymedicines.com Phone(781) 301-7277FaxN/AEmployees224Year Founded2015Price Target and Rating Average Stock Price Forecast$8.73 High Stock Price Forecast$20.00 Low Stock Price Forecast$2.10 Forecasted Upside/Downside+595.4%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,010,000.00 Net Margins-3,926.25% Pretax Margin-3,694.11% Return on Equity-64.66% Return on Assets-51.75% Debt Debt-to-Equity RatioN/A Current Ratio8.30 Quick Ratio8.30 Sales & Book Value Annual Sales$3.21 million Price / Sales17.73 Cash FlowN/A Price / Cash FlowN/A Book Value$2.63 per share Price / Book0.37Miscellaneous Outstanding Shares57,790,000Free Float44,791,000Market Cap$56.92 million OptionableNot Optionable Beta-0.06 Social Links Key ExecutivesAlbert SeymourPresident, Chief Executive Officer & DirectorW. Bradford SmithTreasurer, Chief Financial & Business OfficerJulie JordanChief Medical OfficerMichael BlumChief Commercial OfficerDeborah KinchChief Development OfficerKey CompetitorsGain TherapeuticsNASDAQ:GANXAdageneNASDAQ:ADAGEnochian BiosciencesNASDAQ:ENOBAnebulo PharmaceuticalsNASDAQ:ANEBBiora TherapeuticsNASDAQ:BIORView All CompetitorsInsiders & InstitutionsRBF Capital LLCSold 16,212 shares on 5/16/2023Ownership: 0.102%BlackRock Inc.Sold 104,034 shares on 5/12/2023Ownership: 2.082%Bank of America Corp DEBought 61,968 shares on 5/12/2023Ownership: 0.733%Renaissance Technologies LLCSold 23,936 shares on 5/12/2023Ownership: 0.535%Dimensional Fund Advisors LPSold 21,872 shares on 5/12/2023Ownership: 0.235%View All Insider TransactionsView All Institutional Transactions FIXX Stock - Frequently Asked Questions Should I buy or sell Homology Medicines stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Homology Medicines in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FIXX shares. View FIXX analyst ratings or view top-rated stocks. What is Homology Medicines' stock price forecast for 2023? 6 equities research analysts have issued 1 year target prices for Homology Medicines' stock. Their FIXX share price forecasts range from $2.10 to $20.00. On average, they predict the company's stock price to reach $8.73 in the next year. This suggests a possible upside of 786.1% from the stock's current price. View analysts price targets for FIXX or view top-rated stocks among Wall Street analysts. How have FIXX shares performed in 2023? Homology Medicines' stock was trading at $1.26 on January 1st, 2023. Since then, FIXX shares have decreased by 21.8% and is now trading at $0.9850. View the best growth stocks for 2023 here. Are investors shorting Homology Medicines? Homology Medicines saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 268,800 shares, a decline of 23.4% from the April 30th total of 351,000 shares. Based on an average daily volume of 154,100 shares, the days-to-cover ratio is presently 1.7 days. Currently, 0.6% of the shares of the stock are sold short. View Homology Medicines' Short Interest. When is Homology Medicines' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023. View our FIXX earnings forecast. How were Homology Medicines' earnings last quarter? Homology Medicines, Inc. (NASDAQ:FIXX) issued its quarterly earnings results on Thursday, March, 9th. The company reported ($0.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by $0.09. The company had revenue of $0.80 million for the quarter, compared to analyst estimates of $1.05 million. Homology Medicines had a negative trailing twelve-month return on equity of 64.66% and a negative net margin of 3,926.25%. What other stocks do shareholders of Homology Medicines own? Based on aggregate information from My MarketBeat watchlists, some companies that other Homology Medicines investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Gossamer Bio (GOSS), Spero Therapeutics (SPRO), Alector (ALEC), Dynavax Technologies (DVAX), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO). When did Homology Medicines IPO? (FIXX) raised $100 million in an initial public offering on Wednesday, March 28th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI acted as the underwriters for the IPO and BTIG was co-manager. What is Homology Medicines' stock symbol? Homology Medicines trades on the NASDAQ under the ticker symbol "FIXX." Who are Homology Medicines' major shareholders? Homology Medicines' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (2.08%), Bank of America Corp DE (0.73%), Renaissance Technologies LLC (0.54%), Connor Clark & Lunn Investment Management Ltd. (0.30%), Dimensional Fund Advisors LP (0.23%) and FMR LLC (0.13%). Insiders that own company stock include Albert Seymour, Arthur Tzianabos, Kush Parmar, Michael Lee Blum, Paul Alloway, Timothy P Kelly and W Bradford Smith. View institutional ownership trends. How do I buy shares of Homology Medicines? Shares of FIXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Homology Medicines' stock price today? One share of FIXX stock can currently be purchased for approximately $0.99. How much money does Homology Medicines make? Homology Medicines (NASDAQ:FIXX) has a market capitalization of $56.92 million and generates $3.21 million in revenue each year. The company earns $-5,010,000.00 in net income (profit) each year or ($2.20) on an earnings per share basis. How many employees does Homology Medicines have? The company employs 224 workers across the globe. How can I contact Homology Medicines? Homology Medicines' mailing address is ONE PATRIOTS PARK, BEDFORD MA, 01730. The official website for the company is www.homologymedicines.com. The company can be reached via phone at (781) 301-7277. This page (NASDAQ:FIXX) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Homology Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.